MedPath
HSA Approval

LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML

SIN17212P

LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML

LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML

March 26, 2025

TA BIOSCIENCES PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTA BIOSCIENCES PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01FF13

Manufacturer Information

TA BIOSCIENCES PTE. LTD.

Suzhou Union Biopharm Co., Ltd

Active Ingredients

Toripalimab

240mg/6mL

Toripalimab

Documents

Package Inserts

LOQTOZI PI.pdf

Approved: May 13, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML - HSA Approval | MedPath